mProX™ Human MAP3K11 Stable Cell Line

Sub Cat	Product Name	Target Protein Species	Host Cell Type	Assay Types	Inquiry	Datasheet
S01YF-1122-KX1224	Magic™ Human MLK3(MAP3K11) in Vitro Assay	Human		Kinase Assay

Product Information

Target Family

Kinases/Enzyme

Target Protein Species

Human

Host Cell Type

HEK293;CHO-K1;SAS

Target Classification

Kinase Cell Lines

Gene ID

Human:4296

UniProt ID

Human:Q16584

Product Properties

Biosafety Level

Level 1

Activity

Yes

Quantity

10⁶ cells per vial

Applications

The gene MAP3K11 has been found to play a role in multiple applications. In the study of diagnosing atherosclerosis with rheumatoid arthritis, MAP3K11 was identified as one of six immune-related hub genes that could be used for the construction of a nomogram and for diagnostic efficacy assessment. In the treatment of childhood nephrotic syndrome, machine learning algorithms identified MAP3K11 as one of eight single-nucleotide polymorphisms (SNPs) associated with the efficacy of the drug tacrolimus. In the context of oral squamous cell carcinoma, MAP3K11 was found to facilitate autophagy activity and was correlated with malignancy of cancer cells. Additionally, in a study on cardiovascular physiology, the MLK3 CRIB domain, which includes MAP3K11, was found to be critical for regulating blood pressure, cardiac hypertrophy, and left ventricular function. Overall, these studies suggest that MAP3K11 may have applications in diagnosing atherosclerosis with rheumatoid arthritis, predicting the efficacy of drugs for childhood nephrotic syndrome, assessing malignancy in oral squamous cell carcinoma, and regulating cardiovascular physiology.

Protocols

Please visit our protocols page.

Customer Reviews

There are currently no Customer reviews or questions for mProX™ Human MAP3K11 Stable Cell Line (S01YF-1023-PY7). Click the button above to contact us or submit your feedback about this product.

FAQ

chat Taylor Garcia (Verified Customer)

How does MAP3K11 function as a tumor suppressor? Jul 29 2022

chat Patrick Liam (Creative Biolabs Scientific Support)

MAP3K11 acts as a tumor suppressor and is targeted by the oncomiR miR-125b in early B cells, indicating its role in suppressing tumor development. Jul 29 2022

chat Taylor Miller (Verified Customer)

What is the impact of MAP3K11 expression on autophagy and cancer progression? Jan 09 2022

chat Patrick Liam (Creative Biolabs Scientific Support)

Higher expression of MAP3K11 in tumor tissues compared to normal tissues has been correlated with oral squamous cell carcinoma progression and autophagy activity. Jan 09 2022

Published Data

Fig.1 Knockdown of MAP3K11increased SQSTM1 protein levels and diminished autophagic fluxaccording to alteration of MAP1LC3-II levels

For 72 hours, SAS cells were subjected to siRNA-mediated silencing targeting MAP3K11, followed by treatment with 20 μM of CQ three hours prior to harvest, enabling the investigation of the impact of MAP3K11 depletion on ATG4B and the assessment of autophagic flux through immunoblotting. Autophagic flux was determined by comparing the net alteration in MAP1LC3-II levels in the presence and absence of CQ, employing cells transfected with scramble siRNA (siCtrl) as the control group.

Ref: Liu, Pei-Feng, et al. "MAP3K11 facilitates autophagy activity and is correlated with malignancy of oral squamous cell carcinoma." Journal of Cellular Physiology 237.11 (2022): 4275-4291.

Pubmed: 36103355

DOI: 10.1002/jcp.30881

Research Highlights

Liu, Fuze. et al. "Identification of immune-related genes in diagnosing atherosclerosis with rheumatoid arthritis through bioinformatics analysis and machine learning." Frontiers in immunology, 2023.
The current research shows that the progression of atherosclerosis (AS) may be intensified by rheumatoid arthritis (RA). The objective of this study was to identify potential diagnostic genes for individuals experiencing both AS and RA. By analyzing genetic markers, the study aimed to provide insight into the mechanisms underlying the co-occurrence of these two conditions. The findings of this study have the potential to aid in the development of targeted treatments for individuals with concomitant AS and RA.
Liu, Fuze. et al. "Identification of immune-related genes in diagnosing atherosclerosis with rheumatoid arthritis through bioinformatics analysis and machine learning." Frontiers in immunology, 2023.
Pubmed: 36969166 DOI: 10.3389/fimmu.2023.1126647

Mo, Xiaolan. et al. "Tacrolimus in the treatment of childhood nephrotic syndrome: Machine learning detects novel biomarkers and predicts efficacy." Pharmacotherapy, 2023.
The variability of pharmacokinetics and pharmacodynamics of tacrolimus (TAC) presents challenges in its optimal utilization. Furthermore, there is a lack of effective models for early prediction of TAC efficacy in patients with nephrotic syndrome (NS). The current study aims to identify key factors influencing TAC efficacy and develop predictive models for NS in pediatric patients using machine learning techniques.
Mo, Xiaolan. et al. "Tacrolimus in the treatment of childhood nephrotic syndrome: Machine learning detects novel biomarkers and predicts efficacy." Pharmacotherapy, 2023.
Pubmed: 36521865 DOI: 10.1002/phar.2749